Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease

Acta Neuropathologica

Volumn 130, Issue 4, 2015, Pages 487-499

  Xiang, Yang ^a   Bu, Xian Le ^a   Liu, Yu Hui ^a   Zhu, Chi ^a   Shen, Lin Lin ^a   Jiao, Shu Sheng ^a   Zhu, Xiao Yan ^b   Giunta, Brian ^c   Tan, Jun ^c   Song, Wei Hong ^d   Zhou, Hua Dong ^a   Zhou, Xin Fu ^e   Wang, Yan Jiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Alzheimer s disease; Amyloid beta; Clearance; Kidney; Liver; Parabiosis; Periphery

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; CASPASE 3; INTERLEUKIN 1; INTERLEUKIN 6; IODINE 125; MEMBRANE PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 93; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPSIN I; SYNAPTOPHYSIN; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; RADIOACTIVE IODINE;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; BLOOD SAMPLING; CATABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOSIS; HUMAN; MALE; MIDDLE AGED; MOUSE; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; PARABIOSIS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RADIOACTIVITY; REJUVENATION; SUPERIOR CAVA VEIN; VASCULAR AMYLOIDOSIS; WILD TYPE; AGED; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; YOUNG ADULT;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MICE, TRANSGENIC; MIDDLE AGED; PEPTIDE FRAGMENTS; PRESENILIN-1; YOUNG ADULT;

EID: 84942365599     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-015-1477-1     Document Type: Article

References (51)

1. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM (2007) Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 10:1538–1543. doi:10.1038/nn2014
2. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Alzheimer Disease Neuroimaging I, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL (2013) CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci 16:848–850. doi:10.1038/nn.3435
3. Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, Liang CR, Wang QH, Wang X, Cao HY, Yi X, Deng B, Liu CH, Xu J, Zhang LL, Gao CY, Xu ZQ, Zhang M, Wang L, Tan XL, Xu X, Zhou HD, Wang YJ (2014) A study on the association between infectious burden and Alzheimer’s disease. Eur J Neurol. doi:10.1111/ene.12477
4. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA (2005) Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433:760–764. doi:10.1038/nature03260
5. Deng J, Hou H, Giunta B, Mori T, Wang YJ, Fernandez F, Weggen S, Araki W, Obregon D, Tan J (2012) Autoreactive-Abeta antibodies promote APP beta-secretase processing. J Neurochem 120:732–740. doi:10.1111/j.1471-4159.2011.07629.x
6. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer’s Disease Cooperative Study Steering C, Solanezumab Study G (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311–321. doi:10.1056/NEJMoa1312889
7. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563–1572
8. Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, Frangione B (2004) Systemic catabolism of Alzheimer’s Abeta40 and Abeta42. J Biol Chem 279:45897–45908. doi:10.1074/jbc.M407668200
9. Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP, Hersh LB (2009) Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer’s disease. J Neurosci Res 87:1462–1473. doi:10.1002/jnr.21944
10. Harris RB (1999) Parabiosis between db/db and ob/ob or db/+ mice. Endocrinology 140:138–145. doi:10.1210/endo.140.1.6449
11. Harris RB, Martin RJ (1984) Specific depletion of body fat in parabiotic partners of tube-fed obese rats. Am J Physiol 247:R380–R386
12. Henderson SJ, Andersson C, Narwal R, Janson J, Goldschmidt TJ, Appelkvist P, Bogstedt A, Steffen AC, Haupts U, Tebbe J, Freskgard PO, Jermutus L, Burrell M, Fowler SB, Webster CI (2014) Sustained peripheral depletion of amyloid-beta with a novel form of neprilysin does not affect central levels of amyloid-beta. Brain 137:553–564. doi:10.1093/brain/awt308
13. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405. doi:10.1016/S1474-4422(15)70016-5
14. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73:768–774. doi:10.1212/WNL.0b013e3181b6bb95
15. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Science translational medicine 4:147ra111. doi:10.1126/scitranslmed.3003748
16. Ito S, Ohtsuki S, Murata S, Katsukura Y, Suzuki H, Funaki M, Tachikawa M, Terasaki T (2014) Involvement of insulin-degrading enzyme in insulin- and atrial natriuretic peptide-sensitive internalization of amyloid-beta peptide in mouse brain capillary endothelial cells. J Alzheimer’s Dis: JAD 38:185–200. doi:10.3233/JAD-122077
17. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159–170. doi:10.1093/hmg/ddh019
18. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157–165
19. Kyrkanides S, Tallents RH, Miller JN, Olschowka ME, Johnson R, Yang M, Olschowka JA, Brouxhon SM, O’Banion MK (2011) Osteoarthritis accelerates and exacerbates Alzheimer’s disease pathology in mice. J Neuroinflammation 8:112. doi:10.1186/1742-2094-8-112
20. Li S, Deng J, Hou H, Tian J, Giunta B, Wang Y, Sawmiller D, Smith A, Sanberg PR, Obregon D, Mori T, Tan J (2014) Specific antibody binding to the APP672-699 region shifts APP processing from alpha- to beta-cleavage. Cell Death Dis 5:e1374. doi:10.1038/cddis.2014.336
21. Liu Y, Studzinski C, Beckett T, Guan H, Hersh MA, Murphy MP, Klein R, Hersh LB (2009) Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther 17:1381–1386. doi:10.1038/mt.2009.115
22. Liu Y, Studzinski C, Beckett T, Murphy MP, Klein RL, Hersh LB (2010) Circulating neprilysin clears brain amyloid. Mol Cell Neurosci 45:101–107. doi:10.1016/j.mcn.2010.05.014
23. Liu YH, Bu XL, Liang CR, Wang YR, Zhang T, Jiao SS, Zeng F, Yao XQ, Zhou HD, Deng J, Wang YJ (2015) An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J Neuroinflammation. doi:10.1186/s12974-015-0379-4
24. Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ (2012) Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol 8:465–469. doi:10.1038/nrneurol.2012.118
25. Liu YH, Wang YR, Xiang Y, Zhou HD, Giunta B, Manucat-Tan NB, Tan J, Zhou XF, Wang YJ (2015) Clearance of amyloid-beta in Alzheimer’s disease: shifting the action site from center to periphery. Mol Neurobiol 51:1–7. doi:10.1007/s12035-014-8694-9
26. Liu YH, Xiang Y, Wang YR, Jiao SS, Wang QH, Bu XL, Zhu C, Yao XQ, Giunta B, Tan J, Zhou HD, Wang YJ (2015) Association between serum amyloid-beta and renal functions: implications for roles of kidney in amyloid-beta clearance. Mol Neurobiol 52:115–119. doi:10.1007/s12035-014-8854-y
27. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523:337–341. doi:10.1038/nature14432
28. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ (1994) Passage of human amyloid beta-protein 1-40 across the murine blood–brain barrier. Life Sci 55:1643–1650
29. Nagele RG, Clifford PM, Siu G, Levin EC, Acharya NK, Han M, Kosciuk MC, Venkataraman V, Zavareh S, Zarrabi S, Kinsler K, Thaker NG, Nagele EP, Dash J, Wang HY, Levitas A (2011) Brain-reactive autoantibodies prevalent in human sera increase intraneuronal amyloid-beta(1-42) deposition. J Alzheimers Dis 25:605–622. doi:10.3233/JAD-2011-110098
30. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43:436–441. doi:10.1038/ng.801
31. Nilsson LN, Gografe S, Costa DA, Hughes T, Dressler D, Potter H (2012) Use of fused circulations to investigate the role of apolipoprotein E as amyloid catalyst and peripheral sink in Alzheimer’s disease. Technol Innov 14:199–208. doi:10.3727/194982412X13462021398010
32. Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, Johanson CE, Silverberg GD (2011) Amyloid-beta transporter expression at the blood–CSF barrier is age-dependent. Fluids Barriers CNS 8:21. doi:10.1186/2045-8118-8-21
33. Passos GF, Medeiros R, Cheng D, Vasilevko V, Laferla FM, Cribbs DH (2013) The bradykinin B1 receptor regulates Abeta deposition and neuroinflammation in Tg-SwDI mice. Am J Pathol 182:1740–1749. doi:10.1016/j.ajpath.2013.01.021
34. Picken MM (2001) The changing concepts of amyloid. Arch Pathol Lab Med 125:38–43. doi:10.1043/0003-9985(2001)125<0038:TCCOA>2.0.CO;2
35. Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO (2003) Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol 29:106–117
36. Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, Ovod V, Munsell LY, Mawuenyega KG, Miller-Thomas MM, Moran CJ, Cross DT 3rd, Derdeyn CP, Bateman RJ (2014) Amyloid-beta efflux from the central nervous system into the plasma. Ann Neurol 76:837–844. doi:10.1002/ana.24270
37. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V (2012) Withania somnifera reverses Alzheimer’s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109:3510–3515. doi:10.1073/pnas.1112209109
38. Seliger SL, Siscovick DS, Stehman-Breen CO, Gillen DL, Fitzpatrick A, Bleyer A, Kuller LH (2004) Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol: JASN 15:1904–1911
39. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J Clin Investig 106:1489–1499
40. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D (2003) Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2:506–511
41. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Menard J, Zetterberg H, Wisniewski T, de Leon MJ (2015) Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 11:457–470. doi:10.1038/nrneurol.2015.119
42. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Despres S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T (2011) The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477:90–94. doi:10.1038/nature10357
43. Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D, Wabl R, Udeochu J, Wheatley EG, Zou B, Simmons DA, Xie XS, Longo FM, Wyss-Coray T (2014) Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 20:659–663. doi:10.1038/nm.3569
44. Walker JR, Pacoma R, Watson J, Ou W, Alves J, Mason DE, Peters EC, Urbina HD, Welzel G, Althage A, Liu B, Tuntland T, Jacobson LH, Harris JL, Schumacher AM (2013) Enhanced proteolytic clearance of plasma Abeta by peripherally administered neprilysin does not result in reduced levels of brain Abeta in mice. J Neurosci: Off J Soc Neurosci 33:2457–2464. doi:10.1523/JNEUROSCI.3407-12.2013
45. Wang YJ (2014) Alzheimer disease: lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol 10:188–189. doi:10.1038/nrneurol.2014.44
46. Wang YJ, Pollard A, Zhong JH, Dong XY, Wu XB, Zhou HD, Zhou XF (2009) Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer’s disease. Neurobiol Aging 30:364–376. doi:10.1016/j.neurobiolaging.2007.06.013
47. Wang YJ, Zhou HD, Zhou XF (2006) Clearance of amyloid-beta in Alzheimer’s disease: progress, problems and perspectives. Drug Discov Today 11:931–938
48. Wilcock DM, Gordon MN, Morgan D (2006) Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 1:1591–1595. doi:10.1038/nprot.2006.277
49. Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T (2009) Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci: Off J Soc Neurosci 29:11393–11398. doi:10.1523/JNEUROSCI.2021-09.2009
50. Yao XQ, Jiao SS, Saadipour K, Zeng F, Wang QH, Zhu C, Shen LL, Zeng GH, Liang CR, Wang J, Liu YH, Hou HY, Xu X, Su YP, Fan XT, Xiao HL, Lue LF, Zeng YQ, Giunta B, Zhong JH, Walker DG, Zhou HD, Tan J, Zhou XF, Wang YJ (2015) p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer’s disease. Mol Psychiatry. doi:10.1038/mp.2015.49
51. Zeng F, Lu JJ, Zhou XF, Wang YJ (2011) Roles of p75NTR in the pathogenesis of Alzheimer’s disease: a novel therapeutic target. Biochem Pharmacol 82:1500–1509. doi:10.1016/j.bcp.2011.06.040